Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of the phase 2b FASCINATE-2 trial

Rohit Loomba[1], Wen-Wei Tsai[2], Shipra Vinod Gupta[2], Katharine Grimmer[2], Eduardo Bruno Martins[2], Pierre Bedossa[3], Dean Tai[4], Marie O'Farrell[2], George Kemble[2], Madhavi Rudraraju[5], Eric Lawitz[6], Jose Cobiella[7], Mary E. Rinella[8]

1. MASLD Research Center, University of California San Diego, La Jolla, CA, USA, 2. Sagimet Biosciences Inc, San Mateo, CA, USA, 3. Liverpat, Paris, France, 4. HistoIndex Pte Ltd, Teletech Park, Singapore, 5., Pinnacle Clinical Research, San Antonio, TX, USA, 6. Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA, 7. Global Research Associates, Homestead, FL, USA. 8. University of Chicago, Chicago, IL, USA

Introduction

- Denifanstat (TVB-2640) is an oral, once-daily, selective FASN inhibitor in clinical development for MASH
- FASN inhibition targets 3 hallmarks of MASH: inhibits liver fat synthesis & accumulation (hepatocytes), inhibits fibrosis (hepatic stellate cells require DNL for activation) and decreases inflammation (inflammasome activation by palmitate)[1]
- Denifanstat has recently demonstrated statistically significant MASH resolution and fibrosis improvement in the Phase 2b MASH trial, FASCINATE-2 (NCT04906421)[2]



Background & Aims

- Denifanstat improved liver fibrosis in MASH patients with F2/F3 fibrosis as assessed by both conventional histopathology and AI-based digital pathology[2]
- We aimed to identify a subpopulation of MASH patients with advanced fibrosis (qFibrosis stage 4) using AI-based digital pathology to explore liver pathology and biomarker improvements with denifanstat treatment in this subset of patients

Methods

FASCINATE-2 Phase 2b trial design



ITT: Intention-to-treat
mITT: Modified intention-to-treat

- FASCINATE-2: A total of 168 patients with biopsy-confirmed MASH and F2/F3 fibrosis were randomized 2:1 to once daily oral denifanstat 50 mg or placebo for 52 weeks
- Biopsy evaluation: Liver biopsies pre- and post-treatment were read by a central pathologist using MASH CRN criteria
- Digital pathology: An unstained biopsy slide was evaluated by second harmonic generation (SHG) AI digital pathology (HistoIndex) to identify patients with baseline qFibrosis stage 4 (qF4)
- All analyses involving qF4 patients were conducted post-hoc

Results

Improvement in Liver Fibrosis Without Worsening of MASH (Conventional Pathology)



Cochran-Mantel-Haenszel Test – Two sided at the 0.05 significance level; mITT population[2]

85% of qF4 Patients on Denifanstat Showed 1 to 2-Stage Reductions in qFibrosis Stage



11/13 (85%) qF4 patients decreased by 1 or 2 qFibrosis stages measured by AI-based pathology vs. 1/3 (33%) in placebo (p = 0.015)

5/11 of qF4 patients showed ≥1 stage fibrosis regression, with 4 of these being 2-stage, measured by conventional pathology

qF4 patients were identified using AI-based digital pathology by HistoIndex

Denifanstat Reduced Multiple Non-Invasive Test Biomarkers in qF4 patients



Conclusions

- Denifanstat demonstrated a robust anti-fibrotic effect as measured by both conventional pathology and AI-based digital pathology
- Denifanstat reduced fibrosis and multiple non-invasive biomarkers associated with histological improvements in steatosis and inflammation in patients with advanced fibrosis defined as qF4 by AI-based digital pathology
- These findings support the continued clinical evaluation of denifanstat in MASH patients with advanced fibrosis, including compensated liver cirrhosis

References
(1) O'Farrell et al., 2022. Scientific Reports. doi:10.1038/s41598-022-19459-z
(2) Loomba et al., 2024. The Lancet Gastroenterology & Hepatology. doi:10.1016/S2468-1253(24)00246-2